| BAX |
Report |
Q2 2026 Total Revenue |
BEAT |
pred ~$2.87B vs. cons $2.84B |
MEDIUM |
| BAX |
Report |
Q2 2026 Adjusted EPS |
BEAT |
pred ~$0.39 vs. cons $0.36 |
MEDIUM |
| BAX |
Report |
Q2 2026 Adjusted Operating Margin |
IN-LINE |
pred ~14.2% vs. cons ~14.3% |
LOW |
| BAX |
Guide |
FY2026 Reported Sales Growth |
UNCHANGED |
guide ~flat-to-1% vs. cons ~0.3% (FY2026) |
HIGH |
| BAX |
Guide |
FY2026 Adjusted EPS |
BETTER |
guide ~$1.90-$2.05 (~$1.98 midpoint) vs. cons $1.92 (FY2026) |
MEDIUM |
| BAX |
Guide |
H1-to-H2 Operating Margin Expansion Bridge |
UNCHANGED |
guide ~500bps vs. prior guide ~500bps (H2 2026 vs H1 2026) |
HIGH |
| BAX |
Guide |
Year-End Net Leverage Target |
UNCHANGED |
guide ~3.0x vs. prior target 3.0x (YE2026) |
HIGH |
| BAX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.8% |
— |
MEDIUM |
| BAX |
Return |
5-day cumulative residual |
-4.5% (FADE) |
BAX enters the print up ~48% since April and trading above the average sell-side price target ($24.70 vs $22.96), so even a modest headline beat (EPS ~$0.39 vs $0.36) is likely already priced in, while management's own framing that Q2 margin headwinds would be 'more pronounced' before H2 recovery caps upside surprise on the metric investors care about most (operating margin/H2 bridge). The new two-segment reporting structure adds near-term confusion to segment-level comparability, likely delaying sell-side model updates and full-year EPS revisions. With Injectables & Anesthesia supply constrained into 2027 and Novum IQ hold still unresolved, any initial pop from a headline beat/guide reaffirmation is likely to fade over the week as analysts reconcile recast segment margins, temper targets back toward the ~$23 average, and out-period math (limited 2027 supply recovery, still-pressured leverage path) keeps a lid on follow-through buying. |
MEDIUM |